[February 14, 2017]

QuintilesIMS Reports Fourth-Quarter and Full-Year 2016 Results, Issues First-Quarter and Full-Year 2017 Guidance

Quintiles IMS Holdings, Inc. (NYSE:Q), a leading global provider of information, technology services and contract research to the healthcare and life sciences industries, today reported financial results for the quarter and full-year ended December 31, 2016. On October 3, 2016, the merger of Quintiles Transnational Holdings Inc. and IMS Health Holdings, Inc. was completed. To aid investors and analysts with year-over-year comparability for the merged business, we are providing combined company financial information, which combines the stand-alone Quintiles and IMS Health financial information for revenue and Adjusted EBITDA as if the merger had taken place on January 1, 2015, with conforming adjustments to the current year presentation.

Fourth-Quarter 2016 Operating Results

Revenue for the fourth quarter of $1,953 million increased 74.2 percent on a constant currency basis and 73.1 percent on a reported basis, compared to the fourth quarter of 2015. Under purchase accounting rules, a portion of IMS Health's deferred revenue, which would have otherwise been realized as revenue in future periods, must be eliminated. Excluding this deferred revenue adjustment, and on a combined company basis, revenue for the fourth quarter increased 4.2 percent on a constant currency basis and 3.5 percent at actual FX rates.

Commercial Solutions revenue increased 927.4 percent in the fourth quarter on a constant currency basis and 921.0 percent on a reported basis versus the same period last year. Excluding the $55 million deferred revenue adjustment, the legacy IMS Commercial business had revenues of $860 million and grew 6.9 percent at constant currency and 6.1 percent at actual FX rates. The legacy Quintiles Commercial business had revenues of $74 million and declined 14.0 percent at constant currency and 14.2 percent at actual FX rates. Combined company Commercial Solutions revenue of $934 million grew 4.9 percent in the fourth quarter at constant currency and 4.2 percent at actual FX rates.

Combined company Research & Development Solutions revenue of $882 million grew 6.6 percent on a constant currency basis and 5.4 percent at actual FX rates.

Combined company Integrated Engagement Services revenue of $192 million declined 8.4 percent at constant currency and 6.7 percent at actual FX rates.

Adjusted EBITDA of $541 million improved 129.2 percent on a constant currency basis and 133.7 percent on a reported basis, compared to the fourth quarter of 2015. On a combined company basis, Adjusted EBITDA improved 14.5 percent at constant currency and 16.7 percent at actual FX rates compared to the fourth quarter of 2015.

Fourth-quarter 2016 net loss was $178 million and loss per share was 0.74. This loss was primarily due to a one-time deferred tax charge relating to certain changes in our assertion regarding reinvestment of foreign earnings. Adjusted Net Income was $266 million and Adjusted Diluted Earnings per Share was $1.09 in the fourth quarter.

"For our first quarter as a combined company, we delivered a strong operational performance and achieved financial results in line with or above our targets," said Ari Bousbib, chairman and CEO, QuintilesIMS. "The post-merger integration process is advancing well and we are pleased with our progress to date."

Full-Year 2016 Operating Results

Revenue of $5,364 million for the full year of 2016 increased 24.2 percent on a constant currency basis and 24.0 percent reported, compared to the full year of 2015. On a full-year combined company basis, and excluding the deferred revenue adjustment, revenue of $7,783 million for the full year of 2016 increased 7.8 percent on a constant currency basis and 7.4 percent at actual FX rates.

Commercial Solutions revenue increased 241.6 percent on a constant currency basis and 239.8 percent on a reported basis. On a combined company basis, and excluding the deferred revenue adjustment, the legacy IMS Commercial business had revenues of $3,224 million and grew 11.3 percent at constant currency and 10.5 percent at actual FX rates. The legacy Quintiles Commercial business had revenues of $291 million and declined 9.6 percent on a constant currency basis and 9.8 percent at actual FX rates. Combined company Commercial Solutions revenue of $3,515 million increased 9.1 percent at constant currency and 8.5 percent at actual FX rates.

Research & Development Solutions revenue of $3,472 million grew 10.6 percent on a constant currency basis and 9.9 percent at actual FX rates. Research & Development Solutions contracted net new business totaled approximately $4.3 billion for the 12 months ended December 31, 2016. Contracted backlog was approximately $9.5 billion at December 31, 2016, stated at end of period exchange rates. The company expects approximately $2.9 billion of this backlog to convert to revenue in the next twelve months.

Integrated Engagement Services revenue of $796 million declined 7.9 percent at constant currency and 5.8 percent at actual FX rates.

Adjusted EBITDA of $1,244 million increased 40.5 percent on a constant currency basis and 46.3 percent on a reported basis, compared to the full year of 2015. On a full-year combined company basis, Adjusted EBITDA of $1,956 million increased 9.1 percent on a constant currency basis and 12.6 percent at actual FX rates.

Financial Position

As of December 31, 2016, cash and cash equivalents were $1,198 million and the principal amount of debt was $7,219 million, resulting in net debt of $6,021 million. At the end of the fourth quarter, QuintilesIMS's Gross Leverage Ratio was 3.7 times, and net Leverage Ratio was 3.1 times trailing 12-month combined company Adjusted EBITDA.

Share Repurchase

QuintilesIMS repurchased $1.0 billion of its stock during the fourth quarter of 2016. On February 12, 2017, the QuintilesIMS board authorized an increase of the post-merger share repurchase authorization by $1.0 billion to a total of $2.5 billion, with $1.5 billion authorization remaining.

2017 Full-Year and First-Quarter Guidance

For full-year 2017, QuintilesIMS provides the following guidance:

For the first quarter of 2017, QuintilesIMS provides the following guidance at actual FX rates:

QuintilesIMS revenue guidance includes an estimate for a non-cash accounting adjustment in connection with the merger that is expected to reduce the Commercial Solutions segment and QuintilesIMS first-quarter 2017 revenue and full-year 2017 revenue by approximately $7 million. Under purchase accounting rules, a portion of IMS's deferred revenue, which would have otherwise been realized as revenue in future periods, must be eliminated. This estimate is subject to change upon completion of purchase accounting.

This financial guidance assumes current foreign currency exchange rates remain in effect for the remainder of the year. Revenue guidance excludes reimbursed expenses.

Webcast & Conference Call Details

QuintilesIMS will host a conference call at 9:00 a.m. Eastern Time today to discuss its fourth-quarter and full-year 2016 financial results and 2017 guidance. To participate, please dial 1-800-616-7436 in the United States and Canada or +1-303-223-4394 outside the United States approximately 15 minutes before the scheduled start of the call. The conference call and a presentation will be accessible live via webcast on the Investors section of the QuintilesIMS website at http://ir.quintilesims.com. An archived replay of the webcast will be available online at http://ir.quintilesims.com after 1:00 p.m. Eastern Time today.

About QuintilesIMS

QuintilesIMS (NYSE:Q) is a leading integrated information and technology-enabled healthcare service provider worldwide, dedicated to helping its clients improve their clinical, scientific and commercial results. Formed through the merger of Quintiles Transnational and IMS Health, QuintilesIMS's approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking to improve real-world patient outcomes through treatment innovations, care provision and access can leverage QuintilesIMS's broad range of healthcare information, technology and service solutions to drive new insights and approaches. QuintilesIMS provides solutions that span clinical to commercial, bringing customers a unique opportunity to realize the full potential of innovations and advanced healthcare outcomes.

As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights. Through a wide variety of privacy-enhancing technologies and safeguards, QuintilesIMS protects individual privacy while managing information to drive healthcare forward. These insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders in the development and approval of new therapies, and to identify unmet treatment needs and understand the safety, effectiveness and value of pharmaceutical products in improving overall health outcomes. To learn more, visit www.QuintilesIMS.com.

Cautionary Statements Regarding Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words. Actual results may differ materially from our expectations due to a number of factors, including, but not limited to, that our ability to integrate the legacy IMS Health and Quintiles businesses successfully and to achieve anticipated cost savings and other synergies; the possibility that other anticipated benefits of the proposed transaction will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of the combined company's operations, and the anticipated tax treatment; possible disruptions from the combination of IMS Health and Quintiles through a "merger of equals" business combination that could harm our businesses, including current plans and operations; our ability to retain, attract and hire key personnel; potential adverse reactions or changes to relationships with clients, employees, suppliers or other parties resulting from the merger; that most of our contracts may be terminated on short notice, and we may be unable to maintain large client contracts or to enter into new contracts; our financial results may be adversely affected if we underprice our contracts, overrun our cost estimates or fail to receive approval for or experience delays in documenting change orders; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; failure to meet our productivity objectives; failure to successfully invest in growth opportunities; imposition of restrictions on our current and future activities under data protection and privacy laws; breaches or misuse of our or our outsourcing partners' security or communication systems; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; consolidation in the industries in which our clients operate; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the risks associated with operating on a global basis, including fluctuations in the value of foreign currencies relative to the U.S. dollar, and the ability to successfully hedge such risks; general economic conditions in the markets in which we operate, including financial market conditions; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. For a further discussion of the risks relating to the combined company's business, see the "Risk Factors" in our quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2016, filed with the SEC, as such factors may be amended or updated from time to time in our subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

Note on Non-GAAP Financial Measures

Non-GAAP results, such as adjusted EBITDA, adjusted net income and adjusted diluted EPS, are presented only as a supplement to the company's financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the company's financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the company's results of operations as determined in accordance with GAAP. Definitions and reconciliations of non-GAAP measures to the most directly comparable GAAP measures are provided within the schedules attached to this release. The company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more reliable indicator of the underlying operating performance of the business. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the company's results of operations as determined in accordance with GAAP.

QUINTILESIMSFIN

Click here to subscribe to Mobile Alerts for QuintilesIMS.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170214005502/en/

[ Back To TMCnet.com's Homepage ]